INTRODUCTION AND OBJECTIVES: The insertion of double J ureteral catheters is a common practice in modern urology. Unfortunately, different symptoms may occur with indwelling stents, such as dysuria, hematuria, flank and suprapubic pain. The objective of the present study was to evaluate the safety and efficacy of levobupivacaine as an intravesical instillation in the control of pain and urinary symptoms generated by the ureteral stent.
INTRODUCTION AND OBJECTIVES: The insertion of double J ureteral catheters is a common practice in modern urology. Unfortunately, different symptoms may occur with indwelling stents, such as dysuria, hematuria, flank and suprapubic pain. The objective of the present study was to evaluate the safety and efficacy of levobupivacaine as an intravesical instillation in the control of pain and urinary symptoms generated by the ureteral stent.
METHODS: 77 patients with double J catheter (Percuflex 26/6 TM, Boston Scientific) after endoscopic treatment of an ureteral stone were randomized into 2 groups. Both groups received standard therapy for catheter discomfort management (paracetamol, ketorolac and tamsulosine) . At the end of the procedure group 1 received instillation of 30 cc of saline and group 2 received a dose of 150 mg (30 cc) of intravesical levobupivacaine. Surgeon and patient were blinded for type of instillation received. Symptomatology was evaluate at 4 and 24 hours after the procedure and at the moment of catheter removal. The USSQ survey, in its Spanish-validated version, was used for this purpose. Plasma levels of levobupivacaine were measured at 5, 10, 15 and 20 minutes after instillation in both groups.
RESULTS: Both groups were comparable in terms of age, location and size of stone treated , duration of procedure, stone free rate and days of catheter permanence. Statistical analysis showed significant reduction in group 2 regarding the intensity of pain at 4 hours postoperatively (p ¼ 0.02). In addition, during the catheter carrying period, those patients in whom the levobupivacaine solution was applied had less alteration in work activities (p ¼ 0.03), and less discomfort in the sexual sphere (p ¼ 0.01) Plasma levels of levobupivacaine in the 40 patients exposed to the drug were undetectable (<0.1 mg / dL). There were no side effects attributable to intravesical levobupivacaine.
CONCLUSIONS: To our knowledge this is the first clinical trial using levobupivacaine in bladder instillation, which demonstrate better pain control in the immediate postoperative period. There is a significant effect on daily life parameters that could allow better tolerance to the catheter during the time it should remain installed. Also, the use of this substance does not imply a higher cost and its safe, without side effects.
Source of Funding: Chilean Association of Urology

MP75-08 USE OF NON-METALLIC LONG TERM STENTS FOR URETERAL OBSTRUCTION
Amar P. Patel*, Jeffrey Pearl, John G. Pattaras, Atlanta, GA INTRODUCTION AND OBJECTIVES: Metallic stents have been shown to be advantageous for chronic ureteral obstruction. Nonmetallic stents have historically been used for short term applications due to their propensity to encrust and obstruct. We present our 8-year experience with a novel non-metallic stent with a 365-day dwell time.
METHODS: Since 2008 we placed Bard Optima (Covington, GA) stents for ureteral obstruction in patients not deemed suitable for definitive surgical management. Goal was to exchange stents annually. Indications included e malignant obstruction (11), calculus stricture (10), retroperitoneal fibrosis (5), radiation injury (3), ileal-ureter anastomotic stricture (2) and ureteral pelvic junction (2). Patients underwent initial cystoscopy and placement of 7F stent with subsequent upsizing to 8F. Initially stents were exchanged every 6-9 months, but with experience we exchanged them annually, unless the patient became symptomatic. Patency was evaluated by passage of wire through the stent lumen.
RESULTS: From 2008 to 2016, twenty-four patients and 32 renal units were managed by long-term stent placement. Total of 112 stents were exchanged in this time. Shortest and longest dwell times were 70 days and 742 days, respectively. Exterior stent encrustations were noted in 23% of exchanges. Nonetheless, stents remained patent in 93% of exchanges, with mean dwell time of 280 days.
CONCLUSIONS: To our knowledge this is the first long term series evaluating non-metallic ureteral stents for long-term placement for various causes of ureteral obstruction. The Bard Optima stent is a good alternative to long-term metallic stents. Compared the metallic stents, Optima stents are placed easily over a wire to facilitate ease of use and adoption. Additionally, cost is substantially lower and patient comfort has been exceptional.
Source of Funding: None
MP75-09 RISK FACTORS FOR RE-INFECTION IN PATIENTS DRAINED WITH DJ STENT FOR URETEROLITHIASIS AND SEPSIS
Eyal Kord*, Yoram Siegel, Amir Cooper, zerifin, Israel; Sivan Hirsh, Tel aviv, Israel; Galina Goltsman, Amnon zisman, zerifin, Israel INTRODUCTION AND OBJECTIVES: Currently, there are no guidelines defining optimal timing for definitive stone treatment in stented patients after an event of acute infection with ureteral stones and following resolution of infection. Objective: to evaluate risk factors for re-infection and re-admission in this sub-set of patients.
METHODS: The records of 176 patients admitted between 2009-2016 due to ureterolithiasis and sepsis that were primarily drained with a DJ stent, were retrospectively reviewed. A comparison was carried out between 128 patients with no re-infection and 48 patients (27%) re-admitted for re-infection in the presence of a ureteral DJ stent prior to definitive stone treatment. Univariate and multivariate analysis were performed.
RESULTS: Mean length of hospitalization due to primary septic episode was 7.4 AE5.3 days. 11.4% (20 patients) required ICU admission. Re-infection rate that required admission was 27.3% (48/176). Mean time to definite stone surgery in patients without re-infection was 72.4AE 46.2 days and for those who were re-admitted with infection 42.1 AE 37.3 days. In multivariate analysis diabetes mellitus (p¼0.02) and previous endourological intervention (p¼0.046) were found to be independent risk factors for re-infection. 38% of patients re-admitted for reinfection do so within 3 weeks following the primary septic episode. Mortality: one case (0.8%) during the primary septic episode and three cases (6.3%) during re-admission.
CONCLUSIONS: Patients who suffer from diabetes or have a history of previous endourological surgery are at risk for re-infection during the period between drainage and definite stone treatment. Reinfection episode is associated with increased risk for mortality. Definite stone treatment within 3 weeks following primary sepsis and drainage may eliminate re-infection rate. Optimal bacteriological and patient systemic measures at the time of definite stone treatment should be define and taken into consideration. . 197, No. 4S, Supplement, Monday, May 15, 2017 proximal or impacted stones. We examined whether a double drug Antibiotic Prophylaxis Treatment (APT), an aminoglycoside and penicillin based on resistant bacteria strains we encounter in our institution may reduce urosepsis post-ureteroscopy. METHODS: Between February 2015 and March 2016, we performed 344 ureteroscopies. Starting September, 2015 we changed the APT for endo-urological procedures according to the bacterial resistance profile in urine cultures at our institution. Inclusion criteria were adult patients referred to ureteroscopic treatment for a urinary stone, with or without prior stenting. Exclusion Criteria included integrated procedures (with PCNL), biopsies, pediatric or pregnant patients. Sepsis was defined as fever above 38.5 degrees Celsius with additional standard criteria (International Sepsis Definitions Conference). All patients had a urine culture taken prior to APT initiation. Fisher's exact test and T-test with a two-tailed P value < 0.05 denoted statistical significance.
Source of
RESULTS: 57 patients were excluded. Group 1 (n¼106) were the last to receive the conventional APT (PO Ciprofloxacin 500mg X 2), while the second group (n¼181) were the first to receive the new regimen (IV Gentamycin 240mg & Ampicillin 1gr X 3) prior to ureteroscopy. 65 patients had a preoperative positive culture. A significant percentage of both groups had a preoperative positive urine culture (29%-group 1; 18%-group 2). Seven out of 9 septic events developed in those patients (P<0.001). Patients undergoing RIRS procedures were at increased risk for a septic event when treated with conventional APT (7/9 events; P<0.01). No significant correlation was found between preoperative kidney drainage (stent or nephrostomy tube) and sepsis.
CONCLUSIONS: Our study demonstrates that a significant portion of patients undergoing ureteroscopic treatment for urinary stones have positive preoperative urine culture, despite previous treatment. Standard, 'one size fits all' APT is not sufficient according to our data. A regimen tailored to the local bacterial resistance strains can lower the rate of sepsis significantly.
Source of Funding: None
MP75-11 RENAL STONE CULTURE AND SENSITIVITY IS A BETTER PREDICTOR OF POTENTIAL UROSEPSIS THAN PELVIC OR MIDSTREAM URINE CULTURE AND SENSITIVITY
KARTHIK TANNERU*, guntur, India; RAHUL DEVRAJ, ramreddy ch, hyderabad, India INTRODUCTION AND OBJECTIVES: Septicemia is a serious complication following percutaneous nephrolithotomy(PCNL) and can occur inspite of sterile preoperative urine culture and prophylactic antibiotics. The aim of the study was to analyze the utility of cultures of mid stream urine(MSU), renal pelvic urine and crushed stones for prediction of urosepsis.
METHODS: We performed a prospective clinical study in consecutive patients undergoing PCNL between April 2015 and Oct 2015. The samples collected for culture and sensitivity (C&S) were 1) MSU one day before surgery, 2) Urine from pelvicaliceal system during percutaneous puncture, and 3) Stone fragments collected during the procedure. All the patients were monitored in the postoperative period for symptoms and signs of urosepsis. The data collected were divided into 3 main groups MSU C&S, pelvic urine C&S and stone C&S and analyzed to determine association with urosepsis.
RESULTS: A total of 83 patients were included. The MSU C&S was positive in 10.8%, pelvic C&S in 13.7% and stone C&S in 30.1% patients. 20 patients had systemic inflammatory response syndrome (SIRS) and 3 patients had septic shock. Out of the 20 with SIRS, 17 cases were stone C&S positive, 6 were pelvic urine C&S positive and 2 patients had positive MSU C&S.
CONCLUSIONS: Stone C&S is a better predictor of potential urosepsis than pelvic urine and MSUC &S which often fail to grow stone colonizing bacteria. We recommend routine collection of stone for C&S for the diagnosis and management of urosepsis after PCNL.
Source of Funding: none
MP75-12 PROSPECTIVE EVALUATION OF STONE FREE RATES BY COMPUTED TOMOGRAPHY AFTER AGGRESSIVE URETEROSCOPY
Noah Canvasser*, Aaron Lay, Elysha Kolitz, Jodi Antonelli, Margaret Pearle, Dallas, TX INTRODUCTION AND OBJECTIVES: Previous retrospective and prospective studies have shown surprisingly low stone free rates (SFR) (approximately 50%) after ureteroscopy (URS) using stringent computed tomography (CT) criteria, although the aggressiveness of fragment extraction was not always quantified. Our goal was to determine SFR by CT after URS and aggressive fragment retrieval,
